Affiliation:
1. Department of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USA
Abstract
We present a case of serious and progressive neuropathy shortly following the administration of the herpes zoster subunit (HZ/su) vaccine, otherwise known as Shingrix. The progressive neuropathy occurred a week following the vaccination and progressed until discharge 16 days post-admittance. The patient’s mild symptoms persist. The development of neuropathy following HZ/su administration is exceedingly rare, with an attributable risk of three cases per million vaccines administered. A black box warning was issued for this indication, although diagnosis and treatment were not confirmed for this patient. Reporting cases like this is crucial for a comprehensive understanding of vaccine risks and to characterize the underlying etiology of these serious adverse events.
Reference13 articles.
1. Herpes Zoster Epidemiology, Management, and Disease and Economic Burden in Europe: A Multidisciplinary Perspective;JohnJohnson;Ther. Adv. Vaccines,2015
2. Health Care Utilization and Cost Burden of Herpes Zoster in a Community Population;Yawn;Mayo Clin. Proc.,2009
3. Maramattom, B.V., and Krishnan, P. (2023, November 10). Guillain-Barré Syndrome Following ChAdOx1-S/nCoV-19 Vaccine—Maramattom—2021—Annals of Neurology—Wiley Online Library. Available online: https://onlinelibrary.wiley.com/doi/10.1002/ana.26143.
4. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine;James;Ann. Pharmacother.,2018
5. Uveitis Sarcoidosis Presumably Initiated after Administration of Shingrix Vaccine;Vante;Cureus,2019